

patients with advanced pancreatic cancer. Clin Cancer Res. 2008 July 15; 14(14):4491-9. PubMed PMID: 18628464

[0508] 152. Peters K; Brain Tumor Fund for the Carolinas. Low-Dose Naltrexone for Glioma Patients. IN: ClinicalTrials.gov [Internet]. Bethesda (Md.): National Library of Medicine (US). 2000-[2011 Feb. 23]. Available from <http://clinicaltrials.gov/ct2/show/NCT01303835>: NCT01303835.

[0509] 153. Constantinou, M; Brown University. Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer. IN: ClinicalTrials.gov [Internet]. Bethesda (Md.): National Library of Medicine (US). 2000-[2012 July 24]. Available from <http://clinicaltrials.gov/ct2/show/NCT01650350>: NCT01650350.

[0510] 154. Lazarevic B, Boezelijn G, Diep L M, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg R E, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskén K A, Karlsen S J. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer. 2011; 63(6):889-98. doi: 10.1080/01635581.2011.582221. Epub 2011 Jun. 29. PMID: 21714686

[0511] 155. University of Toronto. ALA and Prostate Cancer. IN: ClinicalTrials.gov [Internet]. Bethesda (Md.): National Library of Medicine (US). 2000-[2006 Mar. 29]. Available from <http://clinicaltrials.gov/ct2/show/NCT00309439>: NCT00309439.

[0512] All patents, applications, and publications cited in the text above are incorporated herein by reference.

EQUIVALENTS

[0513] Other variations and embodiments of the invention described herein will now be apparent to those of skill in the art without departing from the disclosure of the invention or the coverage of the claims to follow.

The following listing of claims replaces all prior versions of claims in the application:

1.-89. (canceled)

90. A method of treating cancer comprising:
administering a regimen to a subject having cancer,
wherein the regimen comprises:
metronomic cyclophosphamide,
metformin,
alpha-lipoic acid,

curcumin,
genistein,
melatonin, and
naltrexone.

91. The method of claim 90, wherein the cyclophosphamide is administered at a dose of 50 mg/day.

92. The method of claim 90, wherein the metformin is administered at a dose within a range of 50-2000 mg/day.

93. The method of claim 92, wherein the metformin is administered at a dose within a range of 500-1000 mg/day.

94. The method of claim 90, wherein the alpha-lipoic acid is administered at a dose within a range of 300-1200 mg/day.

95. The method of claim 90, wherein the alpha-lipoic acid is R-alpha-lipoic acid and is administered at a dose within a range of 300-1200 mg/day.

96. The method of claim 90, wherein the curcumin is administered at a dose within a range of 1-2400 mg/day.

97. The method of claim 90, wherein the genistein is administered at a dose within a range of 300-600 mg/day.

98. The method of claim 90, wherein the melatonin is administered at a dose of 10 mg/day.

99. The method of claim 90, wherein the naltrexone is administered at a dose within a range of 1.5-4.5 mg/day.

100. The method of claim 90, wherein the cancer is Stage II, Stage III, or Stage IV cancer.

101. The method of claim 90, wherein the cancer is a terminal cancer.

102. The method of claim 90, wherein the cancer comprises a metastasized cancer.

103. The method of claim 90, wherein the cancer comprises solid tumors.

104. The method of claim 90, wherein the cancer comprises tumors of epithelial origin.

105. The method of claim 90, wherein the regimen is administered as an adjunct to another cancer treatment.

106. The method of claim 90, wherein the regimen is administered as an adjunct to chemotherapy.

107. The method of claim 90, wherein the subject is not receiving chemotherapy concurrently.

108. The method of claim 90, wherein the regimen is administered to the subject in one or more cycles.

109. The method of claim 90, wherein the regimen is administered as an adjunct to radiation therapy or surgery.

110. The method of claim 90, wherein the subject has previously received another cancer treatment.

111. The method of claim 90, wherein the subject has previously received radiation therapy or chemotherapy.

* * * * *